Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 1/2004

01-01-2004 | Original Article

Parathyroid hormone levels in pubertal uremic adolescents treated with growth hormone

Authors: Stefano Picca, Marco Cappa, Chiara Martinez, Seyoum Ido Moges, John Osborn, Francesco Perfumo, Gianluigi Ardissino, Roberto Bonaudo, Giovanni Montini, Gianfranco Rizzoni

Published in: Pediatric Nephrology | Issue 1/2004

Login to get access

Abstract

We have previously described severe hyperparathyroidism during the pubertal growth spurt in three uremic adolescents treated with recombinant human growth hormone (rhGH). Here we investigate the possible role of puberty in the genesis of hyperparathyroidism during rhGH treatment of a large cohort of patients. Data from 67 uremic patients treated with rhGH from five Italian pediatric nephrology centers were retrospectively recorded every 3 months starting 1 year before rhGH administration. The mean (±SD) rhGH treatment observation period was 19.9±5.9 months. The mean age at the start of rhGH treatment was 8.3±3.6 years. Of the 67 patients, 15 reached pubertal stage 2 during the 1st year of rhGH treatment and 12 of these 15 progressed to pubertal stage 3. The relative increase in parathyroid hormone (PTH) levels after rhGH initiation was greater in pubertal [1.95, 95% confidence interval (CI) 1.43–2.66] than in prepubertal patients (1.19, 95% CI 1.01–1.40). Increases in PTH levels were significantly different between the two groups (Δ=1.64, 95% CI 1.16–3.19, P=0.007). Multiple regression analysis showed an inverse correlation between PTH and calcium levels and a positive correlation between PTH and pubertal stage 3. There was no correlation with phosphate levels and calcitriol dosage. In conclusion, these results suggest that in uremic adolescents treated with rhGH puberty may influence PTH levels.
Literature
1.
Lanes R, Gunczler P, Esaa S, Weisinger JR (2002) The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study. Clin Endocrinol (Oxf) 57:725–730
2.
Degerblad M, Bengtsson BA, Bramnert M, Johnell O, Manhem P, Rosen T, Thoren M (1995) Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 133:180–188PubMed
3.
Mauras N, Doi SQ, Shapiro JR (1996) Recombinant human insulin-like growth factor I, recombinant human growth hormone and sex steroids: effects on markers of bone turnover in humans. J Clin Endocrinol Metab 81:2222–2226PubMed
4.
Balducci R, Toscano V, Pasquino AM, Mangiantini A, Municchi G, Armeniser P, Terracina S, Prossomariti G, Boscherini B (1995) Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy. Eur J Endocrinol 132:42–46PubMed
5.
Nielsen HK, Jorgensen JO, Brixen K, Christiansen JS (1991) Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: dose-response studies with biosynthetic human GH. Calcif Tissue Int 48:82–87PubMed
6.
Lanes, Degerblad M, Elgindy N, Hall K, Sjoberg HE, Thoren M (1992) Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol (Copenh) 126:387–393
7.
Monson JP, Drake WM, Carroll PV, Weaver JU, Rodriguez-Arnao J, Savage MO (2002) Influence of growth hormone on accretion of bone mass. Horm Res 58 [Suppl 1]:52–56
8.
Saggese G, Igli Baroncelli G, Bertelloni S, Cinquanta L, Di Nero G (1993) Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 122:37–44PubMed
9.
Stamoyannou L, Karachaliou F, Gioureli E, Voskaki E, Mengreli C, Bartsocas CS, Koutselinis A (1997) Effect of growth hormone therapy on bone metabolism of growth hormone deficient children. Eur J Pediatr 156:592–596CrossRefPubMed
10.
Lanzi R, Losa M, Villa I, Gatti E, Sirtori M, Dal Fiume C, Rubinacci A (2003) GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. Eur J Endocrinol 148:185–191PubMed
11.
Bérard E, Crosnier H, Six-Beneton A, Chevallier T, Cochat P, Broyer M on behalf of the French Society of Pediatric Nephrology (1998) Recombinant human growth hormone treatment of children on hemodialysis. Pediatr Nephrol 12:304–310PubMed
12.
Maxwell H, Rees L for the British Association for Paediatric Nephrology (1998) Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. Arch Dis Child 79:481–487PubMed
13.
Sieniawska M, Panczyk-Tomaszewska M, Ziolkowska H, Cholewinski M (1996) Optimal vitamin D adjustment following recombinant human growth hormone. Proceedings of the 3rd Novo Nordisk Workshop on CRI, 28 August 1996. Lausanne, Switzerland, pp 38–43
14.
Tönshoff B, Haffner D, Mehls O, Dietz M, Ruder H, Blum WF, Heinrich U, Stöver B and Members of the German Study Group for Growth Hormone Treatment in Children with Renal Allografts (1993) Efficacy and safety of growth hormone treatment in short children with renal allografts: three years experience. Kidney Int 44:199–207PubMed
15.
Hokken-Koelega ACS, Stijnen T, De Jong MCJW, Donckerwolcke RA, De Muinck Keizer-Schrama SMPF, Blum WF, Drop SLS (1994) Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency. J Clin Endocrinol Metab 79:1185–1190
16.
Hokken-Koelega A, Mulder P, De Jong R, Lilien M, Donckerwolcke R, Groothof J (2000) Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr Nephrol 14:701–706CrossRefPubMed
17.
Kaufman DB (1998) Growth hormone and renal osteodystrophy: a case report. Pediatr Nephrol 12:157–159CrossRefPubMed
18.
Picca S, Perruzza I, Cappa M, Rizzoni G (1997) Secondary hyperparathyroidism is not always an obstacle to improved growth during recombinant human growth hormone treatment (letter). Nephron 75:239–240PubMed
19.
Langman CB, Sailer DE, Cohn RA, Mendley SR, Schnaper HW, Schmeissing KA, Misiewicz MT, Marousek M (1995) Induction of secondary hyperparathyroidism (HPT) with recombinant human growth hormone (rhGH) in growth-stunted children with chronic renal diseases (CRD) (abstract). J Am Soc Nephrol 6:966
20.
Fujisawa Y, Kida K (1996) Effect of growth hormone (GH) therapy on parathyroid hormone metabolism in a girl with GH deficient short stature and chronic renal failure. J Pediatr Endocrinol Metab 9:555–558PubMed
21.
Picca S, Cappa M, Rizzoni G (2000) Hyperparathyroidism during growth hormone treatment: a role for puberty? Pediatr Nephrol 14:56–58CrossRefPubMed
22.
Watkins SL (1996) Bone disease in patients receiving growth hormone. Kidney Int 49 [Suppl 53]:S126–S127
23.
Tanner JM (1962) Growth and adolescence, 2nd edn. Blackwell, Oxford
24.
Ohlsson C, IsgaardJ, Tornell J, Nilsson A, Isaksson OGP, Lindahl A (1993) Endocrine regulation of longitudinal bone growth. Acta Paediatr [Suppl] 391:33–40
25.
Bailey DA, Martin AD, McKay HA, Whiting S, Mirwald R (2000) Calcium accretion in girls and boys during puberty: a longitudinal analysis. J Bone Min Res 15:2245–2250
26.
Krabbe S, Transbol I, Christiansen C (1982) Bone mineral homeostasis, bone growth and mineralisation during years of pubertal growth: a unifying concept. Arch Dis Child 57:359–363PubMed
27.
Tommasi M, Bacciottini L, Benucci A, Brocchi A, Passeri A, Saracini D, D’Agata A, Cappelli G (1996) Serum biochemical markers of bone turnover in healthy infants and children. Int J Biol Markers 11:159–164PubMed
28.
Norris SA, Pettifor JM, Gray DA, Buffenstein R (2001) Calcium metabolism and bone mass in female rabbits during skeletal maturation: effects of dietary calcium intake. Bone 29:62–69CrossRefPubMed
29.
Bonofiglio D, Maggiolini M, Catalano S, Marsico S, Aquila S, Giorno A, Andò S (2000) Parathyroid hormone is elevated but bone markers and density are normal in young female subjects who consume inadequate dietary calcium. Br J Nutr 84:111–116PubMed
30.
Behnke B, Kemper M, Kruse HP, Müller-Wiefel DE (1998) Bone alkaline phosphatase in children with chronic renal failure. Nephrol Dial Transplant 13:662–667CrossRefPubMed
31.
Sanchez CP, Salusky IB, Kuizon DB, Abdella P, Juppner H, Goodman WG (1998) Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int 54:1879–1887PubMed
32.
Haffner D, Schaefer F, Nissel R, Wuhl E, Tönshoff B, Mehls O for the German Study Group for Growth Hormone Treatment in Chronic Renal Failure (2000) Effect of growth hormone treatment on the adult height of children with chronic renal failure. N Engl J Med 343:923–930PubMed
33.
Arisaka O, Arisaka M, Nakayama Y, Fujiwara S, Yabuta K (1995) Effect of testosterone on bone metabolism in adolescent male hypogonadism. Metabolism 44:419–423PubMed
34.
Schaefer F, Veldhuis JD, Stanhope R, Jones J, Schärer K and the Cooperative Study Group on Pubertal Development in Chronic Renal Failure (1994) Alterations in growth hormone secretion and clearance in peripubertal boys with chronic renal failure and after renal transplantation. J Clin Endocrinol Metab 78:1298–1306
35.
Freundlich M, Leal D, Levis S, Montane B, Abitbol C, Strauss J, Zilleruelo G (1999) Peak bone mass (PBM) following long-term pediatric dialysis therapy: a possible protective role for sex-steroid hormones (abstract). J Am Soc Nephrol 10:598A
36.
Panczyk-Tomaszewska M, Ziolkowska H, Debinski A, Sawicki A, Zurowska A, Pietrzyk JA, Roszkowska-Blaim M (2000) Bone metabolism markers and bone histomorphometry in children with chronic renal failure in predialysis period during growth hormone treatment. Pol Merkuriusz Lek 8:264–265PubMed
37.
Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG (1988) Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33:975–982
38.
Panczyk-Tomaszewska M, Ziolkowska H, Debinski A, Sieniawska M (2000) Vitamin D metabolite requirement in dialysed children receiving recombinant human growth hormone. Nephrol Dial Transplant 15:375–378CrossRefPubMed
Metadata
Title
Parathyroid hormone levels in pubertal uremic adolescents treated with growth hormone
Authors
Stefano Picca
Marco Cappa
Chiara Martinez
Seyoum Ido Moges
John Osborn
Francesco Perfumo
Gianluigi Ardissino
Roberto Bonaudo
Giovanni Montini
Gianfranco Rizzoni
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 1/2004
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-003-1283-1

Other articles of this Issue 1/2004

Pediatric Nephrology 1/2004 Go to the issue

Original Article

Fluid overload and acute renal failure in pediatric stem cell transplant patients

Letter to the Editors

Really sterile pyuria with Kawasaki disease?

Original Article

Rapid decline of anti-pneumococcal antibody levels in nephrotic children

Original Article

Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide

Letter to the Editors

Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF

Letter to the Editors

Dent disease with compound heterozygous mutations leading to severe chronic renal failure in a female patient